H]mannose-P-dolichol (MPD).
GDP -mannose is the enzymatic donor for the mannosyl residues of the intermediate M 5 Gn 2 -P-P-Dol, while MPD is the donor for the remaining mannosyl residues forming M 9 Gn 2 -P-P-Dol (Figure 2 ). The presence of multiple mannosyl residues makes this technique very sensitive for detection of G 3 M 9 Gn 2 -P-P-Dol. For example, in the author's laboratory, a single, 100 mm culture dish containing 5 Â 10 6 Chinese hamster ovary (CHO)-K1 cells can generate sufficient [ 3 H]G 3 M 9 Gn 2 -P-P-Dol for multiple high performance liquid chromatography (HPLC) runs with an automated in-line isotope detector. In a pulse-labeling mode this technique can assess LLO synthesis rates, while continuous labeling for longer periods approaches steady state. Although M6P is converted by phosphomannose isomerase to fructose-6-P (F6P), leading to glucose-6-P (G6P), labeling with [2- 3 H]mannose does not extend into these other molecules because isomerization of M6P to F6P results in loss of tritium to [ ]glucose and thus can be used to label the glucosyl residues in G 3 M 9 Gn 2 -P-P-Dol. Other strategies for metabolic labeling of LLOs include labeling of GlcNAc residues with radiolabeled glucosamine and labeling the dolichol moiety with radiolabeled acetate or mevalonate.
Disadvantages of metabolic radiolabeling
However useful, metabolic radiolabeling techniques also have limitations: (i) Since LLO pools generally require up to 20 min to turn over (Hubbard and Robbins 1979) , much longer labeling periods are needed for steady-state compositional analysis.
(ii) Metabolic labeling of LLOs in live animals is challenging because of the difficulty of exposing tissue to sufficiently high concentrations of radioactive precursor. Similar limitations apply for LLOs in cells which may not actively incorporate radioactive precursor due to inhibitory culture conditions, genetic defects, the absence of appropriate transport systems, or inefficient metabolic conversion to nucleotide sugar. (iii) The specific activities of the mannosyl residues in LLOs are much lower than that of the starting material due to isotopic dilution with intracellular mannosyl compounds. Therefore, the identities and relative amounts of individual LLO intermediates can be determined, but additional steps must be taken to establish the actual chemical yield of each LLO intermediate. One approach to this problem has been to determine the exact specific activity of the cell-associated GDP-[ 3 H]mannose, and then apply that value to the radiochemical yield of LLO to calculate the chemical amount (Rush and Waechter 1995 (Rush et al. 2000) . (iv) LLO analyzes of clinical specimens are laborious and time-consuming because of the requirement for metabolic radiolabeling. For example, diagnosis of LLO defects in Type I CDG patients involves collection of a skin biopsy and establishment of fibroblast cultures, rather than immediate analysis of the specimen. (v) Effects of certain alterations (such as attenuation of protein synthesis) on the LLO pathway are very difficult to study because the alterations may block metabolic labeling (Gao and Lehrman 2002b) .
General features of alternatives to metabolic radiolabeling
In theory, the limitations discussed in Disadvantages of metabolic radiolabeling might be circumvented by alternatives that do not require metabolic incorporation of radiolabel. A number of such strategies are listed in Table I . Two of the approaches detect intact LLOs. The other methods detect LLO glycans after release from dolichol-P-P, and involve three steps: (i) chemical modification with a chromophore, fluorophore, or isotope; (ii) chromatographic or electrophoretic separation; and (iii) detection by absorbance, fluorescence, or Fig. 2 . Assembly of G 3 M 9 Gn 2 -P-P-Dol. Flipping steps are denoted with dashed arrows, and polypeptides are denoted with dotted lines. Synthesis starts with Dol-P (solid rectangles), and requires two residues of GlcNAc from UDP-GlcNAc (the first transfer also forming the pyrophosphate linkage), five residues of mannose from GDP-mannose, four residues of mannose from mannose-P-Dol (synthesized from Dol-P and GDP-mannose), and three residues of glucose from glucose-PDol (synthesized from Dol-P and UDP-glucose). Dol-P and G 3 M 9 Gn 2 -P-P-Dol are oriented at the ER cytoplasmic and lumenal faces, respectively, with M 5 Gn 2 -P-P-Dol flipping from the former to the latter (Snider and Rogers 1984; Helenius et al. 2002) . N-linked glycosylation involves cotranslational transfer of glycans from G 3 M 9 Gn 2 -P-P-Dol to asparaginyl residues in Asn-Xaa-Ser/Thr sequons of nascent polypeptides (Hubbard and Ivatt 1981; Kornfeld and Kornfeld 1985) by OT. After transfer of glycan to polypeptide, Dol-P-P is recycled by dephosphorylation to Dol-P. Dol-P can also be generated from dolichol by a CTP-dependent kinase (Schenk et al. 2001) . Fig. 1 . Structure of G 3 M 9 Gn 2 -P-P-Dol. The positions and linkages of glucose (Glc), mannose (Man), and GlcNAc are shown.
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liquid scintillation spectroscopy. However, only a few of these techniques (the final four listed in Table I ) appear facile enough for routine laboratory use with large sample numbers, as well as having modest requirements for equipment and operator expertise. The remainder of this article will focus on these alternatives (Figure 3 ) and review the experiments in which they were used to provide new and important information about LLOs. Teaching dolichol-linked oligosaccharides more tricks enhanced chemiluminescence (ECL)-based assay, can be used to determine the total amount of LLOs with glycans that bind concanavalin A (Con A) and does not require a source of OT (see below). The ECL-based assay is semiquantitative, and involves immobilizing LLO samples at the bottoms of glass tubes, followed by incubation with a Con A-horseradish peroxidase (HRP) conjugate. The tubes are placed in a rack, and in the dark ECL reagent is added to each tube. The rack is then placed over X-ray film, and after developing the film, the intensity of the exposure under each tube is used to determine the relative amount of LLO in the sample.
Analyses of intact
OT assay
Gilmore's laboratory ) also developed a set of procedures utilizing OT to assess the LLO content of a mixture or an enriched preparation. Notably, a quantitative "endpoint assay" was devised, which typically involves incubation of the LLO sample with a 10 to 100-fold excess of Na-Ac-Asn-[ 125 I]Tyr-Thr-NH 2 acceptor peptide under conditions with which essentially all of the lipid-linked glycan is transferred. This assay is extremely sensitive because using iodinated peptide with a specific activity of 15 000 cpm/pmol, ,0.05 pmol of LLO can be detected after HPLC analysis of [ 125 I]glycopeptides. The yeast OT preparation is preferred over other sources of OT because it has a relatively low discrimination for G 3 M 9 Gn 2 -P-P-Dol over LLO intermediates under the conditions used, and it is also free of interfering glucosidase and mannosidase activities. If assessment of heterogeneity of the LLO preparation is not necessary, total [
125 I]glycopeptides can be determined by binding to Con A-agarose. Further, if the specific activity of the [
125 I]acceptor peptide is known, the quantity of each glycopeptide in the preparation can be determined by separation with aminopropyl silica HPLC (giving baseline resolution of glycopeptide products) and liquid scintillation spectroscopy. Since [
125 I]glycopeptides are purified by binding to Con A-agarose before HPLC, glycopeptides with M 2 Gn 2 to G 3 M 9 Gn 2 can be detected.
Development of a LLO purification procedure
Modification of a diethylaminoethyl-cellulose approach (Spiro et al. 1979 ) allowed development of a preparative HPLC procedure for obtaining individual enriched LLOs. The ECL and endpoint methods were used to characterize the LLO fractions obtained . For example, a highly enriched (90 -95%) preparation of G 3 M 9 Gn 2 -P-P-Dol was obtained from pancreas, with G 1 M 9 Gn 2 -P-P-Dol and G 2 M 9 Gn 2 -P-PDol accounting for the remaining LLOs in the preparation. This purification of pancreatic LLOs was an improvement over earlier methods that appeared subject to degradation by glycosidases during isolation. The usefulness of these techniques was also demonstrated by isolation of LLO intermediates from a Saccharomyces cerevisiae mutant strain, Dalg3. The major LLO purified, as expected, was M 5 Gn 2 -P-P-Dol. Interestingly, the assay identified appreciable quantities of G 3 M 7 Gn 2 -P-P-Dol ( Figure 4A ), which was not detected by previous [2- 3 H]mannose labeling of alg3 strains, possibly due to the superior sensitivity of the endpoint assay.
The mechanism, subunit heterogeneity, and substrate specificity of OT The preparative LLO isolation, coupled with the detection methods discussed above, were instrumental for studies on the catalytic mechanism of OT. However, rather than rely upon endpoint techniques, these experiments were not designed to deplete the LLO substrate, and in some cases tested competition between LLO. In a detailed kinetic analysis , the specificity of yeast OT for G 3 M 9 Gn 2 -P-P-Dol over M 9 Gn 2 -P-P-Dol was investigated, using highly purified preparations of each LLO and [
125 I]-acceptor peptide. Distinct catalytic and regulatory (activator) binding sites for LLOs were identified, with the conclusion that binding of either LLO to the regulatory site enhances occupancy of G 3 M 9 Gn 2 -P-P-Dol of the catalytic site. This helped explain why, in isolation, both LLOs were equally good donors, but when mixed in a 1:1 ratio, G 3 M 9 Gn 2 -P-PDol was a 5-fold better donor than M 9 Gn 2 -P-P-Dol. It is also consistent with observations that glycoproteins from mutant yeast strains and animal cells with a homogenous supply of an LLO intermediate are not as extensively hypoglycosylated as might be anticipated if OT was selective for G 3 M 9 Gn 2 -P-P-Dol under all conditions. The very existence of such a mechanism suggests that under normal conditions, LLO pools in some cells may not be predominantly G 3 M 9 Gn 2 -P-P-Dol, but instead may contain G 3 M 9 Gn 2 -P-PDol mixed with a high proportion of LLO intermediates.
Preparation of highly enriched LLOs was also important for establishing the distinct donor substrate specificities of isoforms of mammalian OT, an octomeric enzyme ( Figure 4B ) (Kelleher and Gilmore 2006) . Specifically, isoforms containing the STT3-A subunit were relatively less active, though more selective for G 3 M 9 Gn 2 -P-P-Dol, compared with OT isoforms with the STT3-B subunit (Kelleher et al. 2003) . To demonstrate this, OT preparations from canine pancreatic microsomes were resolved by high-performance ion-exchange (Mono-Q) chromatography into fractions containing either the STT3-A or STT3-B subunits, and in which the other STT3 subunit was undetectable. The enzymatic properties of these OTs were then determined with highly purified LLO preparations. Compared with the STT3-A form of OT, the STT3-B form of OT had 5 -6-fold higher turnover numbers with G 3 M 9 Gn 2 -P-P-Dol, and 17-20-fold higher turnover numbers with M 9 Gn 2 -P-P-Dol. The K m value for acceptor tripeptide was independent of the donor LLO for the STT3-B enzyme. However, the STT3-A enzyme had a higher affinity for acceptor than the STT3-B enzyme when G 3 M 9 Gn 2 -P-P-Dol was the donor, and a lower affinity when M 9 Gn 2 -P-P-Dol was the donor, explaining in large part the differences in turnover number. The use of purified LLOs allowed the demonstration of two-site (catalytic and activator) kinetics for the mammalian enzyme as had been identified with the yeast enzyme discussed above, and the observation that the V max of the STT3-B enzyme was 8 -12-fold higher than that of the STT3-A enzyme. To assess selectivity, mixtures of M 9 Gn 2 -P-P-Dol and G 3 M 9 Gn 2 -P-P-Dol (10:1 ratio) were incubated with each enzyme in competition assays to quantify glycopeptide products and determine a donor preference ratio. Remarkably, G 3 M 9 Gn 2 -peptides were enriched only 2.6-fold (relative to the 10:1 starting mixture) for the STT3-B enzyme, while the MA Lehrman donor preference ratio for the STT3-A enzyme was 14.7-fold ( Figure 4B ). Both were broadly expressed, but some tissue differences were identified (for example, STT3-A was higher in liver and pancreas, tissues with high secretory capacity). Both were found in human dermal fibroblasts, with the STT3-B form accounting for 70% of OT. The abundance of the less-selective form of OT may help explain the observation that, in dermal fibroblasts, OT failed to discriminate significantly between the LLO intermediates M 3-5 Gn 2 -P-P-Dol and G 3 M 9 Gn 2 -P-P-Dol ).
Verification of CDG-Ij
Both the endpoint assay and the preparation of purified G 3 M 9 Gn 2 -P-P-Dol were used to verify a deficiency of UDPGlcNAc:Dolichol-P GlcNAc-1-P transferase (GPT) in CDG Type Ij (Wu et al. 2003) . The expected phenotype of a GPT deficiency is a loss of G 3 M 9 Gn 2 -P-P-Dol, no abnormal accumulation of LLO intermediates, and catalytically normal OT. Initial experiments using [2-3 H]mannose labeling of LLOs suggested that CDG-Ij fibroblasts contained less G 3 M 9 Gn 2 -P-P-Dol than normal, but as discussed above interpretation of this type of result was highly dependent upon the intracellular specific activity of the metabolic label. Using pure exogenously added G 3 M 9 Gn 2 -P-P-Dol, OT in microsomes from a CDG-Ij patient's dermal fibroblasts has the same activity as normal OT. However, when assayed with only endogenous LLO, CDG-Ij OT activity in the endpoint assay was reduced by half. This confirmed that the G 3 M 9 Gn 2 -P-P-Dol supply was deficient in the patient's fibroblasts.
Analysis of LLO pools in genetically diverse unicellular eukaryotes Sequencing the genomes of certain protists (unicellular eukaryotes) has suggested, due to the absence of specific LLO synthesis genes, that these organisms would not synthesize G 3 M 9 Gn 2 -P-P-Dol (Samuelson et al. 2005) . Accumulation of smaller LLOs was predicted: M 5 Gn 2 -P-P-Dol for Trichomonas vaginalis and Entamoeba histolytica, and M 9 Gn 2 -P-P-Dol for Cryptococcus neoformans. These predictions were borne out by the endpoint assay ( Figure 4C ). In these studies the endpoint assays used total cellular membranes in the absence of detergent as an endogenous source of OT, and detected transfer of glycans from endogenous LLOs to exogenously added [ Analyzes of free LLO glycans by conjugation of fluorophores to exposed reducing termini Overview of fluorescence-based LLO detection Two independent techniques have been used to label free LLO glycans at their reducing termini with fluorophores, followed by chromatographic or electrophoretic separation, and then fluorescence detection. Thus, both methods involve release of the glycan (exposing the reducing terminus) from the lipid carrier, and require the prior removal of lipid conjugates that are not related to dolichol pyrophosphate, and/or methods of glycan release that are selective for dolichol pyrophosphatelinked glycans. The endpoint assay discussed above is not subject to this requirement because it only detects lipidlinked saccharides that are true OT substrates, i.e. linked to dolichol-P-P. However, lipid-linked saccharides from cells in which the dolichol moiety is defective and therefore hinders OT reactivity [for example, cells of the lec9 genotype deficient in polyprenol reductase (Rosenwald and Krag 1990) ] might be better studied by fluorescent methods or the solid-state assay discussed above, rather than the endpoint assay.
Identification of CDG-Ik by labeling LLO glycans with 2-aminobenzamide LLO glycans were modified by reductive amination with the fluorophore 2-aminobenzamide (2AB), and fractionated by HPLC with a GlykoSep-N column (Prozyme, Inc., San Leandro, CA; Grubenmann et al. 2004 ). This technique was used to screen CDG-I cell cultures for LLO synthesis mutations that might affect a step preceding the addition of mannosyl residues, in which case a loss of G 3 M 9 Gn 2 -P-PDol might be evident by [2-3 H]mannose labeling, but the associated abnormal LLO would not be detected. 2AB-labeled LLO glycans from normal fibroblasts were identified as G 3 M 9 Gn 2 -2AB, which was almost undetectable in fibroblasts from an unassigned CDG patient. In contrast, samples from the patient's fibroblasts contained abundant quantities of Gn 2 -2AB. Judging from fluorescence yields, the amount of Gn 2 -P-P-Dol from the patient's cells appeared similar to the amount of G 3 M 9 Gn 2 -P-P-Dol in normal cells ( Figure 5A ). This would be expected for a metabolic defect that interfered with addition of the first mannosyl residue. This was confirmed by demonstrating that both Alg1 alleles in the patient were abnormal, leading to a new CDG classification, Type Ik.
2AB analysis of LLOs to determine enzyme activities
Labeling of LLO glycans with 2AB was also used to determine the GDP -mannose dependent activities and specificities of the purified recombinant Alg2 and Alg11 LLO transferases ( Figure 5B ) (O'Reilly et al. 2006) . Beginning with chemoenzymatically-synthesized Man 1 GlcNAc 2 -P-P-Dol, Alg2 was convincingly shown to generate the Man 3 GlcNAc 2 -P-P-Dol biosynthetic intermediate in vitro. The LLO glycans of the Alg2 products were released from pyrophosphate linkage to dolichol, coupled to 2AB, and characterized by HPLC (GlykoSepN with fluorescence detection; Prozyme, Inc.) in conjunction with diagnostic glycosidic digestions. The Man 3 GlcNAc 2 -P-P-Dol made by this approach was also used as substrate for reactions with Alg11. By labeling product LLO (Grubenmann et al. 2004 , reproduced and modified with permission, copyright 2004 Oxford University Press). The bold vertical arrows denote Gn 2 -2AB corresponding to Gn 2 -P-P-Dol, and the bold inverted vertical arrows denote G 3 M 9 Gn 2 -2AB corresponding to G 3 M 9 Gn 2 -P-P-Dol. The material eluting just after Gn 2 -2AB is an impurity. (B) Products of in vitro reactions with Alg2, using M 1 Gn 2 -P-P-Dol (Alg1 product) as substrate, and with Alg11, using M 3 Gn 2 -P-P-Dol (Alg2 product 
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glycans with 2AB, Alg11 was shown to synthesize the Man 5 GlcNAc 2 -P-P-Dol biosynthetic intermediate. In conclusion, this study demonstrated that Alg2 and Alg11 each contribute two mannosyl residues during Glc 3 Man 9 GlcNAc 2 -P-PDol synthesis. Since these four mannosyl residues were the last to be assigned to a specific transferase, the enzymes responsible for each sugar residue in Glc 3 Man 9 GlcNAc 2 -P-P-Dol are now known.
Characterization of LLO glycans by FACE
The general strategies underlying fluorophore-assisted carbohydrate electrophoresis (FACE) have been reviewed (Jackson 1996; Starr et al. 1996) . FACE fluorophores bear amino groups for coupling to reducing termini of saccharides by reductive amination. For oligosaccharides with at least three sugars, separation and detection are achieved with a "profiling" gel after coupling to the fluorophores 7-amino-1,3-naphthalenedisulfonic acid (ANDS) or 8-amino-naphthalene-1,3,6-trisulfonate (ANTS). ANDS and ANTS carry, respectively, two and three anionic sulfate modifications. ANDS may be preferred, due to a higher fluorescence yield. For monosaccharides and disaccharides, separation and detection are accomplished with borate-impregnated "monosaccharide composition" gels after coupling to 2-aminoacridone (AMAC), which lacks sulfate. Thus, AMAC should be used for GlcNAc 1-2 -P-P-Dol, and ANDS or ANTS with Glc 0-3 Man 1-9 GlcNAc 2 -P-P-Dol. In all cases, high percentage polyacrylamide gels in a "mini-gel" format are used with high voltage and cooling. The number of samples run on each gel is determined by the choice of comb used to form wells. Since special low-ultraviolet (UV) absorbing glass plates are used, the fluorescent compounds are detected under UV light without disassembly of gel sandwiches, allowing a series of images to be acquired during the electrophoresis. Sensitivity with a fluorescence scanner equipped with a charged-coupled devise (CCD) camera is in the range of 1 -2 pmol, while simple transilluminators (of the type used to visualize ethidium bromide-stained deoxyribonucleic acid gels) and UV viewing chambers can be used with lower sensitivity. Baseline resolution of oligosaccharides containing up to 14 sugars, and in some cases oligosaccharides with the same sugar composition but different isomeric configuration, can be achieved. Methods and equipment for FACE detection of LLO glycans from cultured cells and tissues have been described (Gao and Lehrman 2002a; . Validation of the technique included chemical and enzymatic assessments of the fluorophore-conjugated LLO glycans, detection of glycan intermediates from cell lines with well-characterized defects in the LLO pathway, incorporation of [2-3 H]mannose label into conjugated glycans, and loss of conjugated glycans by treatment with tunicamycin. Control experiments failed to reveal significant artifactual degradation during isolation of mouse tissue LLO glycans.
FACE analysis of LLO heterogeneity in normal mouse tissues, and of LLO accumulation in mouse models of neuronal ceroid lipofuscinosis (Batten disease) Prior to introduction of the FACE technique, data on LLO compositions in normal animal tissues were highly limited, and dealt mainly with pancreas (Table I) . Since most mouse tissues, as determined by FACE, have roughly 1 nmol LLO/g, FACE-LLO analysis with small fresh or frozen mouse tissue samples is highly feasible (Gao and Lehrman 2002a) . FACE showed that G 3 M 9 Gn 2 -P-P-Dol was the most abundant LLO species in each mouse tissue, reaffirming that the general principles for LLO synthesis discerned from cell culture studies also applied to tissues. However, in kidney and spleen LLO intermediates were relatively abundant, and in aggregate accounted for most of the LLO pool. The total LLO content varied over a ten-fold range, being highest in kidney and lowest in testis and lung.
FACE was useful for reevaluating and extending earlier reports of LLO accumulation in tissues (especially brain) of animals and patients characterized by neuronal ceroid lipofuscinosis (NCL), or Batten disease (reviewed in Cho et al. 2005) . The NCLs are neurodegenerative lysosomal storage diseases associated with accumulation of autofluorescent storage material of uncertain composition. There are eight genetically distinguishable NCL subtypes. The recent acquisition of multiple mouse models of NCL by gene disruption or spontaneous mutation made it feasible to systematically test the accumulation of LLOs in freshly isolated NCL brain, compared with age-matched controls (Cho et al. 2005) . FACE demonstrated accumulation of LLOs (typically M 4-9 Gn 2 -P-P-Dol) in the brains (as well as kidney and liver) of protein palmitoyltransferase 1-deficient (PPT1 2/2; Figure 6A ) and four other mouse models of NCL, but not in three mouse models of nonNCL lysosomal storage disorders. Further, the accumulated mouse NCL brain LLOs had structures consistent with a catabolic pathway because endoglycosidase H-sensitive isomers of M 4-5 Gn 2 -P-P-Dol were detected, while NCL microsomes exhibited no apparent LLO biosynthetic defect. Importantly, brain NCL membranes were a mixture of microsomes of normal density containing normal LLOs with endogenous OT activity, and heavy membranes carrying autofluorescent material as well as the accumulated (degraded) LLOs, without apparent endogenous OT activity. One scenario proposed was failure of the autophagosome or another organelle to completely degrade microsomally-derived LLOs.
FACE analyzes of LLO turnover: effects of translation attenuation and ER stress Synthesis of G 3 M 9 Gn 2 -P-P-Dol from radiolabeled sugar precursors is inhibited by agents that block either transcription (Hubbard and Robbins 1980) or translation (Spiro et al. 1976; Schmitt and Elbein 1979; Grant and Lennarz 1983) . As reviewed (Gao and Lehrman 2002b) , several models were proposed, but elucidation of the mechanism was hampered by the inability to follow the fate of G 3 M 9 Gn 2 -P-P-Dol, precisely because it could no longer be detected by radiolabeling. To address this problem, analysis of the effects of the translation inhibitors cycloheximide and puromycin on LLO synthesis in CHO-K1 cells was performed by metabolic labeling with [2-translation inhibitors; consequently, Dol-P was no longer replenished by recycling of Dol-P-P. Both sets of results strongly supported the proposal for a limited pool of Dol-P (Hubbard and Robbins 1980 (Shang et al. 2007 , reproduced from Journal of Cell Biology, copyright Rockfeller University Press). (C) LLOs in fibroblasts, cultured in conventional medium, from normal, CDG-Ia ( phosphomannomutase deficient), CDG-Ib ( phosphomannose isomerase deficient), or CDG-Ic (glucose-P-dolichol:M 9 Gn 2 -P-P-dolichol glucosyltransferase deficient) individuals (Gao et al. 2005, reproduced and modified with permission, copyright 2005 The American Society of Biochemistry and Molecular Biology). In panels A -C, positions of ANDS-conjugated LLO glycans and glucose oligomers (G 5 -G 7 ) are indicated.
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functional primary Dol-P pool (the limited pool) with a secondary pool that normally was not involved in LLO synthesis, and explained why previous studies using microsomal membranes from cells pretreated with translation inhibitors failed to detect loss of Dol-P.
Translation attenuation is a physiological process, and of particular interest here is PKR-like ER kinase (PERK) (Harding et al. 1999) . PERK is an ER-associated Type I transmembrane kinase with a lumenal domain which senses ER stress (such as that caused by excessive protein misfolding), and consequently drives transautophosphorylation (activation) of PERK's cytoplasmic kinase domain. The substrate of PERK-P is eukaryotic initiation factor (eIF) 2a, which participates in translation initiation. Because eIF2a-P interferes with translation initiation, activation of PERK (as well as other eIF2a kinases) causes translation attenuation. An important consequence is a reduction in the load of client polypeptide, alleviating ER stress. This translation attenuation also affects G 3 M 9 Gn 2 -P-P-Dol pools (Shang et al. 2007 ). Using the approach described above, translation attenuation by activated PERK reduced turnover of G 3 M 9 Gn 2 -P-P-Dol, with extensive loss of [ 3 H]G 3 M 9 Gn 2 -P-P-Dol synthesis but no effect on G 3 M 9 Gn 2 -P-P-Dol detected by FACE ( Figure 6B ). However, the significance of reducing turnover of G 3 M 9 Gn 2 -P-P-Dol during a response to ER stress was not clear. Accumulation of LLO intermediates such as M 2-7 Gn 2 -P-P-Dol is a likely cause of aberrant N-glycosylation, leading to protein folding defects and activation of PERK. Therefore, the effects of ER stress-dependent attenuation of translation on accumulated LLO intermediates were examined. Surprisingly, even mild activation of PERK (20-35% attenuation of translation) strongly promoted extension of M 2 -7 Gn 2 -P-P-Dol intermediates to G 3 M 9 Gn 2 -P-P-Dol, and resulted in modification of nascent polypeptides with G 3 M 9 Gn 2 rather than truncated glycans. Thus, the combined uses of metabolic radiolabeling and FACE to assess the LLO pool in ER-stressed cells demonstrated that PERK can counteract LLO synthesis dysfunction by slowing LLO turnover.
Unexpected complexity from PMM deficiency in CDG-Ia: caveats of low-glucose media CDG-Ia results from mutations in the PMM2 gene encoding phosphomannomutase (PMM). PMM converts M6P (formed by the action of hexokinase upon mannose, or by the action of phosphomannose isomerase upon F6P) to M1P. M1P is condensed with guanosine triphosphate by pyrophosphorylase to GDP -mannose, with pyrophosphate as a byproduct. As discussed earlier, GDP -mannose supplies five mannosyl residues to G 3 M 9 Gn 2 -P-P-Dol directly, and four via MPD (Figure 2) . Several studies reported G 3 M 9 Gn 2 -P-P-Dol biosynthesis defects in CDG-Ia dermal fibroblasts, as well as deficient protein N-linked glycosylation, reviewed in Gao et al. (2005) . These would be expected consequences of PMM deficiency. Paradoxically, other studies examining specific glycoproteins in CDG-Ia fibroblasts found no N-linked glycosylation deficiency. Studies reporting LLO biosynthesis and/or N-glycosylation defects used metabolic radiolabeling approaches, while studies reporting no N-glycosylation defect used antibody methods. A consistent difference between these two sets of studies is that the former used media with low glucose (0-0.5 mM) to enhance metabolic labeling, while the latter set used conventional media with physiological glucose. No metabolic labeling studies of CDG-Ia LLOs in conventional media had been reported, presumably because the incorporation of radioactivity in LLOs would have been too low for reliable detection.
FACE showed that G 3 M 9 Gn 2 -P-P-Dol was efficiently synthesized in CDG-Ia fibroblasts with physiological glucose (Figure 6C ), and that LLO profiles for CDG-Ia fibroblasts were essentially indistinguishable from normal LLO profiles . At 2.5 mM glucose ( just below physiological levels), control fibroblast LLOs lacked significant abnormality by FACE, while CDG-Ia profiles showed strong accumulation of M 5 Gn 2 -P-P-Dol. With 0.5 mM glucose, FACE analysis showed that M 5 Gn 2 -P-P-Dol accumulated and the total amount of LLO was greatly diminished in both cell types. These results led to two important conclusions. First, cultured CDG-Ia fibroblasts did not faithfully reproduce the patients' glycosylation defects. It remains to be determined whether decreased production of M1P is sufficient to account for the glycosylation deficiency in patients' hepatocytes, or whether an additional consequence of PMM deficiency may also play a part. Second, the use of low glucose media should be used with caution. In addition to dermal fibroblasts, unintended effects of such conditions have now been documented by FACE analysis with other cells (Shang et al. 2007 ). Specifically, 20 -30 min culture of CHO-K1 cells and mouse embryonic fibroblasts with 0.5 mM glucose did not qualitatively alter the LLO profile, i.e. G 3 M 9 Gn 2 -P-P-Dol was still the predominant LLO. However, for both cell types there was a significant quantitative decrease of G 3 M 9 Gn 2 -P-P-Dol.
Stimulation of G 3 M 9 Gn 2 -P-P-Dol discharge by M6P Since PMM deficiency in CDG-Ia might be expected to increase M6P, the effect of M6P on LLO synthesis was examined in vitro by both FACE (with CHO-K1 cells and hepatocytes) and labeling with GDP -[ 3 H]mannose (with dermal fibroblasts) . Both techniques yielded the same unexpected result: M6P (but neither M1P, G6P, G1P, nor F6P) caused discharge of G 3 M 9 Gn 2 -P-P-Dol (but no other LLOs) from the ER membrane, with appearance of free G 3 M 9 Gn 2 . Stoichiometric FACE measurements showed a several-fold excess of free G 3 M 9 Gn 2 over G 3 M 9 Gn 2 -P-PDol generated during a 1-h incubation, indicating that Dol-P-P released by the action of M6P on G 3 M 9 Gn 2 -P-P-Dol was recycled to Dol-P for additional rounds of G 3 M 9 Gn 2 -P-P-Dol synthesis. This raised the possibility that the glycosylation defect of CDG-Ia patients might be due to a synergistic effect, with M6P causing excessive discharge of G 3 M 9 Gn 2 -P-P-Dol, and replacement by new G 3 M 9 Gn 2 -P-P-Dol synthesis being hindered due to a deficient supply of M1P for synthesis of GDP -mannose.
Future perspectives
For most investigators, metabolic labeling of LLOs with radioactive sugar precursors should remain the primary approach. However, the alternatives reviewed above can be used to complement radiolabeling. Novel applications of these alternatives are anticipated for the near future. These include analyses of tissues in CDG-I animal models, as well as animal models
Teaching dolichol-linked oligosaccharides more tricks for neuronal storage disorders, muscular dystrophies, metabolic syndrome, and other diseases potentially involving LLOs; diagnosis of CDG-I patient material immediately after biopsy; analyzes of LLOs in extracts of pathogenic microbes that are too hazardous to safely transport or that do not incorporate radiolabel; and testing of novel hypotheses requiring facile quantitative LLO measurements. The ability to transport and analyze LLOs in unlabeled extracts should facilitate collaborative studies because regulatory hurdles regarding the exchange of live cultures can be avoided.
